One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The RX mirror permits severe impairment; retrieved DailyMed and manufacturer safety wording do not. The mirror prints April 2024; DailyMed has a January 2026 header but an April 2022 PI revision.
What to reconcile: Hold the more permissive RX instruction for exact-label reconciliation. Do not treat header/retrieval dates as new label revisions or prescribe from the disputed extract.
Open this note and its source referencesThe current RX recheck remains permissive in severe impairment; the retrieved DailyMed renal section remains restrictive. Header and retrieval dates do not establish a new prescribing-information revision.
What to reconcile: Continue holding the disputed RX instruction. This release does not claim exact controlling-label reconciliation.
Open this note and its source referencesThe official label still does not recommend severe impairment or ESRD with or without dialysis. The RX mirror could not be reliably re-read in this pass.
What to reconcile: Retain the historical discrepancy and the printed renal-measure limitation. Reproductive-potential restrictions remain separate.
Open this note and its source referencesNo adjustment is recommended for mild/moderate impairment, MDRD eGFR 30-89 as printed in the label. Use is not recommended with severe impairment (15-29) or ESRD (below 15), with or without dialysis, because safety data are insufficient.
The subsection prints mL/min without the indexing denominator despite naming MDRD; retain that source limitation rather than silently substituting Cockcroft-Gault. The official restriction remains confirmed. The RX mirror was not reliably re-read in this pass, so its historical disagreement is not closed. Reproductive-potential, pregnancy and lactation contraindications remain separate.
RDM57-official-oteseconazole-vivjoa-07fd066c0a-C1 · Source locator: Sections 4 and 8.6
Selected sections only; not a complete prescribing monograph or independent clinician approval.
Exact DailyMed HTML identity and named sections checked. Raw SPL XML, original document hash and complete revision history were not obtained.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=oteseconazole-vivjoa&s1=RDM57-official-oteseconazole-vivjoa-07fd066c0a&h1=d3274c8f114760247a9059214655c209b27bfd3f25d85d88ff9b7739be348e29